Horizon Global Corporation (NYSE:HZN), one of the world's leading manufacturers of branded towing and trailering equipment, today announced that the Company's Board of Directors has authorized the review of
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression